Efficacy and safety benefits of <scp>HR17031</scp> , a fixed‐ratio combination of <scp>INS068</scp> and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentr
HR17031 is effective and well-tolerated in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug.
Authors
- Qing‐Yuan Sun (ORCID: https://orcid.org/0000-0002-0148-2414)
- Linong Ji (ORCID: https://orcid.org/0000-0003-1305-1598)
- Li Lü (ORCID: https://orcid.org/0000-0002-3905-1273)
- Quanren Wang
- Dong Xue (ORCID: https://orcid.org/0000-0002-7969-7386)
- Zi Ye (ORCID: https://orcid.org/0009-0002-7196-6411)
- Li Mao (ORCID: https://orcid.org/0009-0004-7243-8017)
- Dandan Huang (ORCID: https://orcid.org/0000-0002-6578-1835)
- Zhao Shi (ORCID: https://orcid.org/0000-0002-9427-9609)
- Xiang Lin (ORCID: https://orcid.org/0000-0002-8141-4015)
- Xiaodong Sun
Institutions
- Weifang Medical University (CN)
- Peking University (CN)
- Huaian First People’s Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Peking University People's Hospital (CN)
- Yueyang Second People's Hospital (CN)
- Yueyang Hospital (CN)
- Central Hospital of Wuhan (CN)
- Jiangsu Hengrui Medicine (China) (CN)
- Third Hospital of Changsha (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1111/dom.70036
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Hengrui Medicine